Business Context and Reporting Period
CareDx, Inc. filed this Form 8-K on May 4, 2018, to disclose the entry into a Material Definitive Agreement. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Transaction Terms
This filing details a strategic partnership rather than periodic financial results. Key financial terms of the agreement include:
- Initial Payment: $5.0 million paid to Illumina, Inc.
- Royalties: Mid-single to low-double digits on future sales of commercialized products.
- Commitments: Minimum purchase commitments for finished products and raw materials through 2023.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes and Strategic Developments
On May 4, 2018, CareDx entered into a License and Commercialization Agreement with Illumina, Inc. This agreement grants CareDx worldwide distribution, development, and commercialization rights for Illumina's next-generation sequencing (NGS) transplant clinical application products. Effective June 1, 2018, CareDx becomes the exclusive worldwide distributor of Illumina's TruSight HLA v1 and v2 product lines and associated Assign HLA software for bone marrow and solid organ transplantation diagnostic testing. Additionally, CareDx secured exclusive rights to develop and commercialize the next generation (v3) of HLA product lines and an NGS product for chimerism detection under the "AlloSeq" branding.
Outlook, Risks, and Contingencies
Management intends to use the AlloSeq branding for the development stage products. The agreement obligates CareDx to complete timely development and commercialization of future products. Illumina has agreed to provide transition and support services. Certain terms of the agreement have been omitted from this report pursuant to a Confidential Treatment Request and will be filed later with the Form 10-Q for the quarter ending June 30, 2018.
Key Facts for Investor Verification
- Verify the impact of the $5.0 million initial payment on the company's cash position in the upcoming 10-Q.
- Confirm the specific royalty percentages within the "mid-single to low-double digits" range once the full agreement is filed.
- Monitor the June 1, 2018, effective date for the exclusive distribution of TruSight HLA products.
- Review the minimum purchase commitments through 2023 for potential future cash flow obligations.
- Check the upcoming Form 10-Q for the full text of the License Agreement and omitted confidential terms.